Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Production / Operations

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Certification Milestone Validates Platform Maturity But Revenue Visibility Remains Constrained

By The Northwire Desk — AI Analysis Apr 14, 2026 · 09:51 SEGN · 0.335 Seegnal Inc.
Executive Summary
  • Seegnal Inc.'s Israeli subsidiary, Seegnal eHealth Ltd., received the Gold Mark from the Standards Institution of Israel on April 14, 2026.
  • The certification recognizes excellence in management systems, processes, and product lifecycles for commercialization readiness.
  • Qualification required holding three specific quality certifications: ISO 13485:2016 (Medical Devices), ISO 27799 (Health Information Security), and ISO 27001:2022 (Information Security).
  • The news serves as an operational update confirming enterprise-grade compliance standards.
  • No new revenue figures, contract values, or specific customer acquisition numbers were disclosed in this release.
Material Impact
  • The Gold Mark certification is a validation of existing claims rather than a catalyst for immediate revenue growth.
  • It supports the February 2026 announcement regarding the expansion at Tel Aviv Sourasky Medical Center by confirming regulatory and security compliance required for large-scale hospital deployments.
  • The news aligns with the January 2026 presentation on real-world evidence, reinforcing the company's narrative of clinical safety and governance.
  • Given the stock price volatility seen in September 2025 (dropping from $1.00 to $0.21), this certification provides stability but lacks the magnitude to be classified as a "Game Changer."
  • The market likely anticipated compliance milestones given the new CEO's focus on enterprise governance and US expansion mentioned in December 2025.
SEGN · Price
Company Overview
  • Company: Seegnal Inc., operating through Israeli subsidiary Seegnal eHealth Ltd.
  • Flagship Project: Prescription Intelligence Platform, a SaaS solution providing real-time, patient-specific medication decision support using explainable AI.
  • Platform Scale: Claims to process >400,000 prescriptions per day with >174 million total prescriptions analyzed and >20,000 clinicians currently using the system.
  • Geographic Reach: Deployed in Israel (national standard), UAE, United Kingdom, United States, and Poland.
  • Product Suite: Includes core decision support and newer modules like "MetricsGuard" for patient-specific risk detection (e.g., hypoglycemia alerts).
Read the original news release →

More from Seegnal Inc.

Jun 25, 2026 · 08:30

Israeli med-tech SaaS expands domestic footprint while navigating severe liquidity constraints and unproven U.S. commercialization.

Other Jun 19, 2026 · 08:30

Seegnal Successfully Initiates First U.S. Pilot Program

Production / Operations Jun 05, 2026 · 08:30

Seegnal Inc. - AI-Driven Prescription Intelligence Platform for Medication Safety

M&A / Property Jun 02, 2026 · 17:00

Seegnal Raises $1.3M at a Discount to Fund Burn Rate as Filing Delays and Going Concern Risks Mount

Financings May 19, 2026 · 08:30

Seegnal Eyes U.S. Expansion Amid Regulatory Filing Overhang

Other May 06, 2026 · 17:00

Filing Default Lingers as Seegnal Pushes Audit Deadline

Regulatory